Page 422 - Read Online

Shamliyan et al. Vessel Plus 2020;4:35 I http://dx.doi.org/10.20517/2574-1209.2020.34 Page 13 of 13

80. Obokata M, Reddy YNV, Borlaug BA. Diastolic dysfunction and heart failure with preserved ejection fraction: understanding
mechanisms by using noninvasive methods. JACC Cardiovasc Imaging 2020;13:245-57.
81. Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Eligibility varies among the 4 sodium-glucose cotransporter-2
inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. Am J Manag Care 2018;24:S138-45.
82. Chetrit M, Cremer PC, Klein AL. Imaging of diastolic dysfunction in community-based epidemiological studies and randomized
controlled trials of HFpEF. JACC Cardiovasc Imaging 2020;13:310-26.
83. Ho JE, Zern EK, Wooster L, et al. Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF
definitions. Circulation 2019;140:353-65.
84. Oh JK, Miranda WR, Bird JG, Kane GC, Nagueh SF. The 2016 diastolic function guideline: is it already time to revisit or revise them?
JACC Cardiovasc Imaging 2020;13:327-35.
85. van der Meer P, Gaggin HK, Dec GW. ACC/AHA versus ESC Guidelines on Heart Failure: JACC Guideline Comparison. J Am Coll
Cardiol 2019;73:2756-68.
86. Wallach JD, Sullivan PG, Trepanowski JF, Sainani KL, Steyerberg EW, Ioannidis JP. Evaluation of evidence of statistical support and
corroboration of subgroup claims in randomized clinical trials. JAMA Int Med 2017;177:554-60.
87. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials:
quantifying the risks of false-positives and false-negatives. Health Technol Assess 2001;5:1-56.
88. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management
of heart failure: a report of the American college of cardiology/american heart association task force on clinical practice guidelines and
the heart failure society of America. J Cardiac Fail 2017;23:628-51.
89. Das SR, Everett BM, Birtcher KK, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction
in patients with type 2 diabetes: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol
2020;76:1117-45.
90. Seferovic PM, Coats AJS, Ponikowski P, et al. European society of cardiology/heart failure association position paper on the role and
safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail 2020;22:196-213.
91. Writing Committee M, Yancy CW, Jessup M, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for
heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of
cardiology/american heart association task force on clinical practice guidelines and the heart failure society of America. Circulation
2016;134:e282-93.
92. Gunawan F, Nassif ME, Partridge C, Ahmad T, Kosiborod M, Inzucchi SE. Relative frequency of cardiology vs. endocrinology visits by
type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering
medications. Cardiovasc Endocrinol Metab 2020;9:56-9.
93. Zoler ML. SGLT2 Inhibitors, developed for T2D, now ‘belong to cardiologists and nephrologists. MedScape. 2020; Medscape Medical
News: Conference News: ADA 2020. Available from: https://www.medscape.com/viewarticle/934107. [Last accessed on 16 Nov 2020]
94. American Diabetes Association Position Statement 10. Cardiovascular disease and risk management: standards of medical care in
diabetes - 2020. Diabetes Care 2020;43:S111-34.
95. American Diabetes Association Position Statement 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of
Medical Care in Diabetes - 2020. Diabetes Care 2020;43:S37-47.
96. International Working Group for HTAA Advancement, Neumann PJ, Drummond MF, Jonsson B, Luce BR, Schwartz JS, et al. Are key
principles for improved health technology assessment supported and used by health technology assessment organizations? Int J Technol
Assess Health Care 2010;26:71-8.
97. Kristensen FB, Lampe K, Chase DL, et al. Practical tools and methods for health technology assessment in Europe: structures,
methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA. Int J Technol Assess
Health Care 2009;25:1-8.
98. World Health Organization. 2015 Global Survey on Health Technology Assessment by National Authorities. ISBN 978 92 4 150974 9.
2015. Available from: https://www.who.int/health-technology-assessment/MD_HTA_oct2015_final_web2.pdf?ua=1. [Last accessed on
16 Nov 2020]
99. Fanourgiakis J, Kanoupakis E. Health technology assessment (HTA): a brief introduction of history and the current status in the field of
cardiology under the economic crisis. J Evid Based Med 2015;8:161-4.
100. Elbarbary M. Health technology assessment (HTA) in cardiac field. J Saudi Heart Assoc 2010;22:77-84.
101. The International Network of Agencies for Health Technology Assessment. The Uniquiness of INAHTA INAHTA Position Statement.
2020. Available from: https://www.inahta.org/position-statements/. [Last accessed on 16 Nov 2020]
102. Yaku H, Ozasa N, Morimoto T, et al. Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome
patients in contemporary real clinical practice in Japan- observations from the prospective, multicenter kyoto congestive heart failure
(KCHF) registry. Circ J 2018;82:2811-9.
103. Parissis J, Farmakis D, Triposkiadis F. Heart failure registries: how far can we go? Euro J Heart Fail 2016;18:626-8.
104. Bassand JP, Apenteng PN, Atar D, et al. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of
stroke. Future Cardiol 2020; doi: 10.2217/fca-2020-0014.
105. Alhabib KF, Gamra H, Almahmeed W, et al. Acute myocardial infarction and acute heart failure in the Middle East and North Africa:
study design and pilot phase study results from the PEACE MENA registry. PLoS One 2020;15:e0236292.